Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Market Cap	184.32B
Revenue (ttm)	13.05B
Net Income (ttm)	4.65B
Shares Out	5.95B
EPS (ttm)	0.78
PE Ratio	39.64
Forward PE	36.52
Dividend	0.34 (1.08%)
Ex-Dividend Date	Jul 3, 2025

Volume	5,354,496
Average Volume	11,668,086
Open	30.85
Previous Close	31.00
Day's Range	30.50 - 31.45
52-Week Range	15.32 - 31.75
Beta	0.65
RSI	69.67
Earnings Date	Aug 26, 2025

About HKG:3692

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2024, HKG:3692's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY